Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Ionis - What They Never Told You

First Approved Alexander Disease Treatment Arrives with a List Price Above One Million Dollars Per Year

FDA approved Zanvastro for Alexander disease. Ionis set the list price at $285,000 per dose, or about $1.14 million a year at quarterly dosing.

Medical Daily

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

MarketBeat

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer therapy. A subgroup taking the drug without stabilizers showed a nominal benefit. This setback impacts a projected two billion dollar sales opportunity.

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through

MarketBeat

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

MarketBeat

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference

Executives at a healthcare investor event outlined commercial launch plans, pipeline readouts and market-development priorities across several biotechnology franchises, with discussion spanning Ionis Pharmaceuticals (NASDAQ:IONS) products including TRYNGOLZA, DAWNZERA and WAINUA, as well as Neurocri

MarketBeat

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

When Insider Selling Is a Good Thing: 2 Stocks to Watch

Ionis Pharmaceuticals and Waste Management insiders sell in early 2026, creating buying opportunities in their stocks while analysts raise price targets.

MarketBeat

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

Benzinga

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released topline results on Monday from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive, and often fatal neurological condition.

Benzinga

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status

On Tuesday, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Ionis Pharmaceuticals Inc.’s (NASDAQ:IONS) ION582 for Angelman syndrome (AS), a rare neurological disorder.

Benzinga

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Benzinga

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

Ionis is shaping up to be one of the most compelling long-term growth stories in biotech today.

Barchart

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Top News

Biogen And Ionis Halt ALS Treatment Development

Biogen and Ionis discontinue ALS treatment development, emphasizing the need for continued research in neurodegenerative diseases.

Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have

Benzinga

Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder

The

People

James Hamilton

36 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.